Cigna Group has struck deals with obesity drug makers Eli Lilly & Co. and Novo Nordisk A/S that aim to widen coverage by limiting how much employer-sponsored health plans have to pay for the medicines.

The agreements by the company's pharmacy benefits manager are part of a pitch to employers alarmed by spiking costs for popular new weight-loss treatments including Novo's Wegovy and Lilly's Zepbound. Cigna says its program will limit spending increases for the class of drugs, known as GLP-1s, to a maximum of 15% annually. The company called it the first such financial guarantee on the market.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform